Photo taken from Jordi Remon/X
Jun 2, 2024, 10:50
Jordi Remon: Comparison of treatments in EGFRm NSCLC at ASCO24
Jordi Remon, a Thoracic oncologist at CIOCC Barcelona, recently posted on X:
“For patients with EGFRm Osi-Progression NSCLC, there is no homogeneous benefit in PFS with antiangiogenic + io+CT vs CT and no mature OS benefit.
Phase 3 HARMONI-3 trial (ivonescimab (bispecific VEGF/PD1 Ab) + CT vs CT is pending. Data in Chinese patients looks similar to previous (HARMONI-A).”
Source: Jordi Remon/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 21:37
Nov 15, 2024, 21:26
Nov 15, 2024, 21:09
Nov 15, 2024, 21:05
Nov 15, 2024, 21:03
Nov 15, 2024, 21:02
Nov 15, 2024, 20:28
Nov 15, 2024, 19:31
Nov 15, 2024, 17:47
Nov 15, 2024, 17:45